Trillium Therapeutics Reports Annual Financial and Operating Results
March 11, 2019 17:09 ET
|
Trillium Therapeutics Inc.
Positive data from the intratumoral trial of TTI-621, a CD47 immune checkpoint inhibitor, presented at the 2018 EORTC CLTF and ASH 2018 meetingsEncouraging signals of activity and tolerability data...
Trillium Announces Closing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units
March 08, 2019 18:37 ET
|
Trillium Therapeutics Inc.
TORONTO, March 08, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for...
Trillium Announces Pricing of US$15 Million Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units
February 22, 2019 09:00 ET
|
Trillium Therapeutics Inc.
TORONTO, Feb. 22, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for...
Trillium Announces Proposed Public Offering of Common Share Units and Series II Non-Voting Convertible First Preferred Share Units
February 21, 2019 16:00 ET
|
Trillium Therapeutics Inc.
TORONTO, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for...
Trillium Therapeutics Provides Update on its Intratumoral TTI-621 Program at the American Society of Hematology 60th Annual Meeting
December 03, 2018 07:00 ET
|
Trillium Therapeutics Inc.
TORONTO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today...
Trillium Therapeutics Reports Third Quarter 2018 Financial and Operating Results
November 14, 2018 07:00 ET
|
Trillium Therapeutics Inc.
Positive clinical update on the intratumoral trial of TTI-621, a CD47 immune checkpoint inhibitor, presented at the 2018 EORTC CLTF meetingPositive clinical update on the intravenous trial of TTI-621...
Trillium Therapeutics to Provide Update on TTI-621 Clinical Programs at Two Scientific Conferences
September 28, 2018 07:00 ET
|
Trillium Therapeutics Inc.
Data from intralesional trial in mycosis fungoides/Sézary syndrome patients continue to show promise, with rapid reductions in CAILS scores in the majority of patients and preliminary evidence of...
Trillium Therapeutics to Present at Upcoming Investor Conferences
September 27, 2018 07:00 ET
|
Trillium Therapeutics Inc.
TORONTO, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...
Trillium Therapeutics Announces Data Presentations at Upcoming Scientific Meetings
September 12, 2018 07:00 ET
|
Trillium Therapeutics Inc.
Updated safety and efficacy data from the TTI-621 intravenous trial at the 16th Annual Discovery on Target ConferenceUpdated data from the TTI-621 intralesional trial in patients with mycosis...
Trillium to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
August 30, 2018 09:30 ET
|
Trillium Therapeutics Inc.
TORONTO, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer,...